J&J: Fast Track status in early-onset Alzheimer's disease

(CercleFinance.com) - Johnson & Johnson announces that the FDA has granted 'Fast Track' designation to posdinemab (its monoclonal antibody directed against phosphorylated tau), currently in phase 2b for the treatment of early-onset Alzheimer's disease.


Posdinemab has demonstrated potential to target disease-associated phosphorylated tau in cerebrospinal fluid and slow the spread of tau aggregates in non-clinical models.

The Fast Track designation underlines the urgency of developing new therapeutic options for this neurodegenerative disease affecting 55 million people worldwide.


Copyright (c) 2025 CercleFinance.com. All rights reserved.